At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
rhPDGF-BB Injection +1 moredrug
Likely dose
rhPDGF-BB Injection 0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomized, Single Ascending Dose, Double-blinded, Placebo Controlled, Multi-center Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis
In Brief
A Phase 2 clinical trial evaluating rhPDGF-BB Injection and Placebo for Lateral Epicondylitis. Completed, enrolled 100 participants across 6 sites.
Detailed Summary
The purpose of this study is to determine whether recombinant human platelet-derived growth factor (rhPDGF-BB) Injection is effective in the treatment of lateral epicondylitis (tennis elbow).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLateral Epicondylitis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 2012
Enrollment StartDec 2012
Primary CompletionOct 2014
TodayJul 2026
First PostedDec 11, 2012
Enrollment StartDec 12, 2012
Primary CompletionOct 21, 2014
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 13.6 years ago
Interventions
rhPDGF-BB Injectiondrug
Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
Placebodrug
sodium acetate buffer (0 mg rhPDGF-BB)